Please login to the form below

Not currently logged in
Email:
Password:

bone disease

This page shows the latest bone disease news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close

Despite a median of three earlier lines of therapy, 42 of patients (74%) achieved a complete response, and of those 39 (68%) tested negative for minimal residual disease (MRD) in their ... All 25 of the patients in the study had undetectable minimal

Latest news

  • Leadiant gets FDA OK for bubble boy disease drug Leadiant gets FDA OK for bubble boy disease drug

    Adagen’s launch in 1990 transformed the treatment of the disease, providing the first alternative to bone marrow transplants for patients. ... News of the approval is a boost to Leadiant, which is currently facing fierce criticism over alleged

  • NICE U-turn on Crystiva for rare bone disease NICE U-turn on Crystiva for rare bone disease

    Reversing its initial decision to reject the drug, NICE has issued a positive recommendation for Kyowa Kirin’s rare disease drug Crystiva, the first treatment approved to target the underlying pathophysiology ... Characterised by bowed or bent legs, a

  • Lilly's abemaciclib data leaves potential uncertain Lilly's abemaciclib data leaves potential uncertain

    inhibitor as initial treatment because some patients – including those with bone metastases or indolent disease - may do well with endocrine therapy alone. ... In our study, nearly one-third of patients had bone metastases only or a tumour relapsing

  • Regeneron says anti-NGF fasinumab works in pain Regeneron says anti-NGF fasinumab works in pain

    placebo on fractures, bone destruction and disease progression. ... specific alkaline phosphatase - a marker of the activity of bone-secreting cells called osteoblasts - in the fasinumab-treated group.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    and juvenile-onset hypophosphatasia, a serious and sometimes fatal bone disease. ... Wellstat Therapeutics. USA. vonicog alfa. Vonvendi. von Willebrand disease. von Willebrand factor (recombinant).

More from news
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials. .

  • Interview with Roch Doliveux, UCB Interview with Roch Doliveux, UCB

    We mimic the gene defect and apply reverse engineering to build quality bone. ... With anti-sclerostin, for example, we had no bone disease expertise in our development organisation, hence we made a partnership with Amgen.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Bone Therapeutics looks to Pfizer for clinical head Bone Therapeutics looks to Pfizer for clinical head

    Heynen will support the firm as it progresses its pipeline of regenerative bone disease and orthopaedic therapies through clinical development and commercialisation. ... disease drug Aricept and medical team leader for its anti-inflammatory drug

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics